USANA Health Sciences (NYSE:USNA) Upgraded at StockNews.com

StockNews.com upgraded shares of USANA Health Sciences (NYSE:USNA) from a buy rating to a strong-buy rating in a report released on Thursday morning.

Separately, DA Davidson cut their price target on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 23rd.

USANA Health Sciences Stock Down 3.8 %

Shares of USANA Health Sciences stock opened at $33.38 on Thursday. The stock has a market capitalization of $636.22 million, a P/E ratio of 11.80, a price-to-earnings-growth ratio of 1.25 and a beta of 0.89. USANA Health Sciences has a 12-month low of $33.28 and a 12-month high of $54.81. The company has a 50-day simple moving average of $37.91 and a 200 day simple moving average of $40.37.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.07. The business had revenue of $200.22 million during the quarter, compared to analyst estimates of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same quarter last year, the business posted $0.59 earnings per share. On average, equities analysts anticipate that USANA Health Sciences will post 2.45 earnings per share for the current year.

Insider Activity at USANA Health Sciences

In other news, Director Gilbert A. Fuller sold 675 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $37.71, for a total transaction of $25,454.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.33% of the stock is owned by insiders.

Hedge Funds Weigh In On USANA Health Sciences

A number of institutional investors have recently added to or reduced their stakes in the company. Safe Harbor Fiduciary LLC bought a new position in USANA Health Sciences during the third quarter worth $30,000. KBC Group NV grew its stake in USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares during the last quarter. BOKF NA raised its holdings in USANA Health Sciences by 99.4% in the 2nd quarter. BOKF NA now owns 5,526 shares of the company’s stock valued at $250,000 after acquiring an additional 2,755 shares during the period. Centiva Capital LP acquired a new stake in USANA Health Sciences during the third quarter worth approximately $213,000. Finally, Quest Partners LLC acquired a new position in shares of USANA Health Sciences in the third quarter valued at approximately $250,000. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.